CN114364679A - 作为Syk和VEGFR2双靶点抑制剂的1H-吡唑衍生物及应用 - Google Patents

作为Syk和VEGFR2双靶点抑制剂的1H-吡唑衍生物及应用 Download PDF

Info

Publication number
CN114364679A
CN114364679A CN202180005288.XA CN202180005288A CN114364679A CN 114364679 A CN114364679 A CN 114364679A CN 202180005288 A CN202180005288 A CN 202180005288A CN 114364679 A CN114364679 A CN 114364679A
Authority
CN
China
Prior art keywords
compound
pharmaceutically acceptable
acceptable salt
compound according
added
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN202180005288.XA
Other languages
English (en)
Other versions
CN114364679B (zh
Inventor
钱文远
王宏健
谭亮
陈曙辉
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Suzhou Aokangweishi Biotechnology Co ltd
Original Assignee
Suzhou Aokangweishi Biotechnology Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Suzhou Aokangweishi Biotechnology Co ltd filed Critical Suzhou Aokangweishi Biotechnology Co ltd
Priority to CN202310540824.7A priority Critical patent/CN116589469A/zh
Publication of CN114364679A publication Critical patent/CN114364679A/zh
Application granted granted Critical
Publication of CN114364679B publication Critical patent/CN114364679B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/541—Non-condensed thiazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

一类脾酪氨酸激酶(Syk)和血管内皮生长因子2(VEGFR2)双抑制剂，具体公开了式(I)所示化合物及其药学上可接受的盐，及其在制备脾酪氨酸激酶(Syk)和血管内皮生长因子2(VEGFR2)双抑制剂相关药物中的应用。

Description

PCT国内申请，说明书已公开。

Claims (16)

  1. PCT国内申请，权利要求书已公开。
CN202180005288.XA 2020-02-24 2021-02-23 作为Syk和VEGFR2双靶点抑制剂的1H-吡唑衍生物及应用 Active CN114364679B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202310540824.7A CN116589469A (zh) 2020-02-24 2021-02-23 作为Syk和VEGFR2双靶点抑制剂的1H-吡唑衍生物及应用

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CNPCT/CN2020/076414 2020-02-24
CN2020076414 2020-02-24
PCT/CN2021/077482 WO2021169958A1 (zh) 2020-02-24 2021-02-23 作为Syk和VEGFR2双靶点抑制剂的1H-吡唑衍生物及应用

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN202310540824.7A Division CN116589469A (zh) 2020-02-24 2021-02-23 作为Syk和VEGFR2双靶点抑制剂的1H-吡唑衍生物及应用

Publications (2)

Publication Number Publication Date
CN114364679A true CN114364679A (zh) 2022-04-15
CN114364679B CN114364679B (zh) 2023-06-09

Family

ID=77490711

Family Applications (2)

Application Number Title Priority Date Filing Date
CN202310540824.7A Pending CN116589469A (zh) 2020-02-24 2021-02-23 作为Syk和VEGFR2双靶点抑制剂的1H-吡唑衍生物及应用
CN202180005288.XA Active CN114364679B (zh) 2020-02-24 2021-02-23 作为Syk和VEGFR2双靶点抑制剂的1H-吡唑衍生物及应用

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CN202310540824.7A Pending CN116589469A (zh) 2020-02-24 2021-02-23 作为Syk和VEGFR2双靶点抑制剂的1H-吡唑衍生物及应用

Country Status (6)

Country Link
US (1) US20230219960A1 (zh)
EP (1) EP4112621A4 (zh)
JP (1) JP7418618B2 (zh)
KR (1) KR20220130747A (zh)
CN (2) CN116589469A (zh)
WO (1) WO2021169958A1 (zh)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117143114A (zh) * 2023-10-30 2023-12-01 深圳大学 一种BRD4和Src双靶点抑制剂及其制备方法与应用

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116648247A (zh) * 2021-02-03 2023-08-25 苏州欧康维视生物科技有限公司 吡唑取代的咪唑并[1,2-a]喹喔啉衍生物的盐型及晶型
CN114591338B (zh) * 2022-03-31 2023-05-09 苏州欧康维视生物科技有限公司 一种Syk和VEGFR2双靶点抑制剂的制备方法及其用途
CN114621232B (zh) * 2022-03-31 2023-03-14 苏州欧康维视生物科技有限公司 一种Syk和VEGFR2双靶点抑制剂的制备方法及其用途
CN116554177B (zh) * 2023-04-24 2024-02-27 苏州欧康维视生物科技有限公司 一种含氮杂环化合物的盐型、晶型及其应用

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1609105A (zh) * 2003-10-22 2005-04-27 中国人民解放军军事医学科学院毒物药物研究所 1－羟甲基咪唑并[1，2－α]喹喔啉化合物及其应用
WO2010135571A1 (en) * 2009-05-20 2010-11-25 Cylene Pharmaceuticals, Inc. Novel protein kinase modulators
CN102413831A (zh) * 2009-04-29 2012-04-11 拜耳医药股份有限公司 取代的咪唑并喹喔啉
CN110194772A (zh) * 2018-07-02 2019-09-03 深圳市塔吉瑞生物医药有限公司 用于抑制蛋白激酶活性的炔基（杂）芳环类化合物

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008518964A (ja) * 2004-11-01 2008-06-05 ユニバーシティ オブ サザン カリフォルニア 癌と、血管新生機能に関連する疾患との治療用新規化合物
CN112225742B (zh) * 2020-12-11 2021-03-09 北京华氏开元医药科技有限公司 一种抑制vegfr活性的化合物、制备方法及应用
CN116648247A (zh) * 2021-02-03 2023-08-25 苏州欧康维视生物科技有限公司 吡唑取代的咪唑并[1,2-a]喹喔啉衍生物的盐型及晶型
CN114591338B (zh) * 2022-03-31 2023-05-09 苏州欧康维视生物科技有限公司 一种Syk和VEGFR2双靶点抑制剂的制备方法及其用途
CN114621232B (zh) * 2022-03-31 2023-03-14 苏州欧康维视生物科技有限公司 一种Syk和VEGFR2双靶点抑制剂的制备方法及其用途

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1609105A (zh) * 2003-10-22 2005-04-27 中国人民解放军军事医学科学院毒物药物研究所 1－羟甲基咪唑并[1，2－α]喹喔啉化合物及其应用
CN102413831A (zh) * 2009-04-29 2012-04-11 拜耳医药股份有限公司 取代的咪唑并喹喔啉
WO2010135571A1 (en) * 2009-05-20 2010-11-25 Cylene Pharmaceuticals, Inc. Novel protein kinase modulators
CN110194772A (zh) * 2018-07-02 2019-09-03 深圳市塔吉瑞生物医药有限公司 用于抑制蛋白激酶活性的炔基（杂）芳环类化合物

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117143114A (zh) * 2023-10-30 2023-12-01 深圳大学 一种BRD4和Src双靶点抑制剂及其制备方法与应用
CN117143114B (zh) * 2023-10-30 2024-02-20 深圳大学 一种BRD4和Src双靶点抑制剂及其制备方法与应用

Also Published As

Publication number Publication date
JP2023518328A (ja) 2023-04-28
JP7418618B2 (ja) 2024-01-19
CN116589469A (zh) 2023-08-15
EP4112621A1 (en) 2023-01-04
EP4112621A4 (en) 2023-08-09
US20230219960A1 (en) 2023-07-13
CN114364679B (zh) 2023-06-09
WO2021169958A1 (zh) 2021-09-02
KR20220130747A (ko) 2022-09-27

Similar Documents

Publication Publication Date Title
CN114364679B (zh) 作为Syk和VEGFR2双靶点抑制剂的1H-吡唑衍生物及应用
JP7022131B2 (ja) ブルトン型チロシンキナーゼのイミダゾピラジン阻害剤
AU2014230943B2 (en) New octahydro-pyrrolo[3,4-c]-pyrrole derivatives and analogs thereof as autotaxin inhibitors
JP6059731B2 (ja) 新規プリン誘導体および疾患の処置におけるその使用
TWI719209B (zh) 嘧啶酪氨酸激酶抑制劑
CN106458912A (zh) 双环稠合的杂芳基或芳基化合物以及它们作为irak4拟制剂的用途
TW201321379A (zh) 吡唑并喹啉（Ｐｙｒａｚｏｌｏｑｕｉｎｏｌｉｎｅ）衍生物
KR20180073682A (ko) 피리미딘 유도체 및 그의 사용
CN105358545A (zh) 杂芳基吡啶酮和氮杂-吡啶酮酰胺化合物
JP2018516970A (ja) ムスカリンｍ２受容体の正のアロステリックモジュレーター
WO2020244614A1 (zh) 吡咯并嘧啶类化合物及其应用
JP2022525749A (ja) Ｊａｋキナーゼ阻害剤及びその調製方法、並びにその医薬分野での使用
KR20240016938A (ko) 포스포이노시티드 3 키나아제 베타 억제제 및 그 조성물 및 방법
CA3207392A1 (en) Cdk inhibitor
CN110734456A (zh) 一种化合物及其制备方法和医药上的应用
WO2021218912A1 (zh) 含苯基并内磺酰胺的化合物
CN105164134A (zh) 作为pde10抑制剂的咪唑并-三嗪衍生物
WO2022070289A1 (ja) ピリミジン含有含窒素二環化合物
US11992494B2 (en) Cyclopentathiophene carboxamide derivatives as platelet activating factor receptor antagonists
US11766443B2 (en) Cyclopentathiophene carboxamide derivatives as platelet activating factor receptor antagonists
CN103517905A (zh) 新型六氢吡咯并咪唑酮化合物
CN110248936A (zh) 化合物
TW202328123A (zh) 含有嘧啶之含氮雙環化合物
CN114957259A (zh) 氰基取代的芳香双环类化合物及其应用
CN115916782A (zh) 化合物及其作为脾酪氨酸激酶抑制剂的应用

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40064681

Country of ref document: HK

GR01 Patent grant
GR01 Patent grant